In vitro, we demonstrated that advanced glycation end-products [AGE, oxidative derivatives resulting from hyperglycemia, whose levels are increased in clinical/experimental diabetes (38–42)] and its receptor (RAGE) are responsible for upregulation of heparanase in PDAC cells. Here, AGER is linked to Hyperglycemia.